Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,627 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
Interventions
Asciminib single agent
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
4
States / cities
New Brunswick, New Jersey • New York, New York • Cincinnati, Ohio + 1 more
Terminated Phase 1Phase 2 Interventional Results available

Glasdegib for Chronic Graft-Versus-Host Disease

NCT04111497
Conditions
Chronic Graft Versus Host Disease, Fasciitis
Interventions
Glasdegib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Durham, North Carolina • Salt Lake City, Utah • Seattle, Washington
Conditions
Infection, Heart Failure, COPD, Asthma, Gout Flare, Chronic Kidney Diseases, Hypertensive Urgency, Atrial Fibrillation Rapid, Anticoagulants; Increased
Interventions
Home hospitalization, Traditional inpatient hospitalization
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Asthma, COPD, Healthy
Interventions
HXe MRI lung ventilation
Drug
Lead sponsor
Xemed LLC
Industry
Eligibility
21 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Completed Phase 3 Interventional Results available

12-week Efficacy of Indacaterol

NCT01072448
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol 75 μg, Placebo to indacaterol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
62
States / cities
Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more
Conditions
Kidney Transplantation, Kidney Disease, Kidney Failure
Interventions
Alemtuzumab, Mycophenolate mofetil, Sirolimus, Tacrolimus, Donor bone marrow stem cell infusion, Kidney transplant
Drug · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Miami, Florida
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
27,190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Andover, Massachusetts
Conditions
Chronic Graft Versus Host Disease
Interventions
Fostamatinib, Ruxolitinib
Drug
Lead sponsor
Stefanie Sarantopoulos, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting No phase listed Observational

Michigan Early Disease Progression Cohort

NCT04968249
Conditions
COPD
Interventions
Observational
Other
Lead sponsor
University of Michigan
Other
Eligibility
30 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
UMEC/VI 62.5/25 mcg via ELLIPTA, UMEC 62.5 mcg via ELLIPTA, Salmeterol 50 mcg via DISKUS, Placebo via ELLIPTA, Placebo via DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
2,696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Lincoln, California • Clearwater, Florida + 34 more
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Not listed No phase listed Observational

CareCOPD - COPD Home Monitoring Study

NCT04918095
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
CareCOPD Platform
Device
Lead sponsor
Cognita Labs LLC
Industry
Eligibility
40 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Ventura, California
Completed Phase 3 Interventional Results available

AMPLIFY - D6571C00001 Duaklir USA Phase III Study

NCT02796677
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg), Aclidinium bromide 400 μg (AB 400 μg), Formoterol fumarate 12 μg (FF 12 μg), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg, Tiotropium 18 μg (TIO 18 μg), Placebo to TIO 18 μg
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
1,595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
85
States / cities
Gulf Shores, Alabama • Phoenix, Arizona • Tucson, Arizona + 74 more
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Interventions
Tiered whole health support for people living with COPD
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Neuromuscular electrical stimulation (NMES)
Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
40 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
BiPAP Synchrony ventilator
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Depemokimab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 75 Years
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
42
States / cities
Newport Beach, California • Lakewood, Colorado • Brandon, Florida + 35 more
Recruiting Phase 2 Interventional

Pulmonary Hypertension SOLAR

NCT04778046
Conditions
Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Asthma, Chronic School Absenteeism
Interventions
Home Visit, Standard Care
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
5 Years to 12 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Results available

Electronic Proactive Outreach for Smokers With COPD

NCT04462289
Conditions
Pulmonary Disease, Chronic Obstructive, Smoking
Interventions
Proactive Outreach
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Asthma, COPD
Interventions
beclamethasone dipropionate, albuterol, Prednisone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Insomnia
Interventions
Eszopiclone, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
65 Years to 85 Years
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
82
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more
Conditions
Asthma, Bronchospasm
Interventions
albuterol inhalation powder, Placebo, albuterol inhalation aerosol
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
San Jose, California • Centennial, Colorado • Denver, Colorado + 1 more
Conditions
Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts